Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891303 | 0.86 | S1PR1 (0.38) | GPR119MTORMAPK1METSYK | |
| SCHEMBL2904085 | 0.86 | GRM2 (0.40) | GPR119MTORMAPK1METGRM2 | |
| SCHEMBL2896254 | 0.85 | GPR119 (0.39) | GPR119MTORMAPK1METSYK | |
| SCHEMBL2894552 | 0.84 | GRIN1 (0.41) | GPR119MTORMAPK1SYKGRM2 | |
| SCHEMBL6523552 | 0.83 | GRM2 (0.40) | GPR119GRM2S1PR1PARP10PARP15 | |
| SCHEMBL2895333 | 0.82 | GPR119 (0.35) | GPR119MTORMAPK1METSYK | |
| SCHEMBL2895345 | 0.81 | GPR119 (0.38) | GPR119MTORMAPK1SYKGRM2 | |
| SCHEMBL2895545 | 0.80 | MAPK1 (0.40) | GPR119MTORMAPK1GRM2PARP10 | |
| SCHEMBL13024338 | 0.80 | MAPK1 (0.36) | GPR119MTORMAPK1SYKGRM2 | |
| SCHEMBL6519362 | 0.80 | GPR119 (0.45) | GPR119MTORGRM2S1PR1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009050523-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286110-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | GPR119, GIPR, GPR39 | GPR119 1/4885MTOR 2703/4885MAPK1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.